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A B S T R A C T
Aims: To characterize ethnic differences in the severity and clinical management of type 2
diabetes at initial diagnosis.
Methods: An observational cohort study of 179,886 people with incident type 2 diabetes
between 2004 and 2017 in the Clinical Practice Research Datalink was undertaken; 63.4%
of the cohort were of white ethnicity, 3.9% south Asian, and 1.6% black. Ethnic differences
in clinical profile at diagnosis, consultation rates, and risk factor recording were derived
from linear and logistic regression. Cox-proportional hazards regression was used to deter-
mine ethnic differences in time to initiation of therapeutic and non-therapeutic manage-
ment following diagnosis. All analyses adjusted for age, sex, deprivation, and clustering
by practice.
Results: In the 12 months prior to diagnosis, non-white groups had fewer consultations
compared to white groups, but risk factor recording was better than or equivalent to white
groups for 9/10 risk factors for south Asian groups and 8/10 risk factors for black groups
(p < 0.002). Blood pressure, BMI, cholesterol, eGFR, and CVD risk levels were more favour-
able in non-white groups, and prevalence of macrovascular disease was significantly lower
(p < 0.003). Time to initiation of antidiabetic treatment and first risk assessment was faster
in non-white groups relative to white groups, while time to risk factor measurement and
diabetes review was slower.
Conclusions: We find limited evidence of systematic ethnic inequalities around the time of
type 2 diabetes diagnosis. Ethnic disparities in downstream consequences may relate to
genetic risk factors, or manifest later in the care pathway, potentially in relation to long-
term risk factor control.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Marked ethnic differences in the risk of long-term vascular
outcomes among people with type 2 diabetes have been
established in UK populations [1,2]. The extent to which
these inequalities stem from modifiable factors such as
healthcare usage or quality of diabetes management
remains unclear. Given that inequalities can accumulate
over time, it is vital to identify where along the care path-
way differences by ethnicity may arise. Though equity of
service provision is a central tenet of the National Health
Service (NHS) [3], recent studies have highlighted ethnic dif-
ferences in access to healthcare, treatment provision and
risk factor control [4–8].
In the UK, the collection of ethnicity data via official
statistics has been mandated since the Race Relations Act
of 1968 as a vital first step towards identifying and actively
tackling ethnic inequalities. The 16 ethnic group categories
defined by the 2001 Census for England and Wales currently
form the national standard for mandatory ethnicity data col-
lection across the National Health Service. Ethnicity is self-
reported by individuals at either initial registration with
their general practitioner or during consultation, and
intended to reflect the individuals own self-perception of
belonging to, or identifying with a certain social group [9,10].
Prior to initial diagnosis, there may be differences by eth-
nicity in consultation rates and measurement of risk factors,
which may impact upon the timeliness of diagnosis and
severity of disease at initial presentation. Delays in diagnosis
may result in delays in initiation of therapeutic and non-
therapeutic management, which may further compound
existing inequalities. Though guidelines exist for managing
type 2 diabetes in the UK, the extent to which these are fol-
lowed may differ by ethnic group, leading to inequalities in
the downstream consequences of type 2 diabetes [8,11]. The
2018 UK national diabetes audit identified inequalities by
age, region, diagnosed serious mental illness and learning
disabilities, but did not explore differences by ethnicity, leav-
ing a critical gap in the evidence base [12].
The aims of this study were to (1) Quantify ethnic differ-
ences in risk factor levels and co-morbidities at the time of
initial diagnosis, (2) Compare consultation rates and com-
pleteness of process of care measures between ethnic groups
in the 12 months preceding type 2 diabetes diagnosis, (3)
Determine whether the time to initiation of therapeutic and
non-therapeutic management following initial diagnosis dif-
fered by ethnic group.
2. Methods
2.1. Study design and population
An observational cohort study utilizing the Clinical Practice
Research Datalink (CPRD) was undertaken. The CPRD is a clin-
ical research database containing anonymised longitudinal
primary care records for approximately 15 million people
from 714 general practices. The CPRD population has been
shown to be representative of the UK population with respect
to age, gender, and ethnicity [13].
Type 2 diabetes was identified using an adjudication algo-
rithm developed to minimize misclassification of diabetes
status and type in electronic health records [14]. Briefly, the
algorithm assigns an initial diabetes type based on clinical
Read codes [15] – C10E for type 1 diabetes and C10F for type
2 diabetes- and then applies a series of logic rules to assign
a final diabetes status by identifying congruent or contradic-
tory evidence on age at diagnosis, diabetes medications (ex-
cluding individuals on metformin only as this may be
indicated for conditions other than type 2 diabetes such as
polycystic ovarian syndrome or pre-diabetes), hypergly-
caemia (HbA1c  6.5% or 48 mmol/mol, or fasting/ random/
unspecified glucose  11.1 mmol/l) and presence of diabetes
process of care codes. For individuals with a prescription for
antidiabetic medication in the 12 months preceding the first
ever type 2 diabetes diagnosis, the diagnosis date was moved
forward to the date of prescription as it was deemed plausible
that the prescription was related to the initial diagnosis. As
misclassification of prevalent diagnoses as incident diagnoses
is more likely around the time of initial registration with the
general practitioner, a minimum registration period of six
months prior to initial diagnosis of type 2 diabetes was
required [16]. Adults aged 18 and over registered between
2004 and 2017, with at least six months of continuous regis-
tration prior to diagnosis of type 2 diabetes (the earliest of
diagnosis date or medication date where applicable) were
included in the study.
2.2. Covariates
Self-reported ethnicity, identified using Read codes, was col-
lapsed into the five categories of the 2001 UK census (white,
south Asian, black African/Caribbean, mixed, and other). For
individuals with more than one ethnicity code on their pri-
mary care record, a previously developed algorithm was used
to assign a best ‘single’ ethnicity – based on the most com-
monly, and most recently recorded codes (Supplementary
material, Figure S1) [17]. Age at diagnosis was calculated by
subtracting year of birth from year of diagnosis. Deprivation
was measured using quintiles of the 2015 Index of Multiple
Deprivation (IMD) – a measure of small area deprivation based
on an individual’s home postcode [18]. For people with linkage
to Office for National Statistics data, quintiles of IMD were
derived from the individual’s home postcode. For the 40% of
people without linkage, quintiles were derived from the post-
code of the individual’s general practice.
Baseline risk factors were identified from the most
recently recorded value in the 12 months preceding type 2
diabetes diagnosis (see supplementary table S3 for all code
lists). These included glycated haemoglobin (HbA1c), fasting
blood glucose (FBG), systolic and diastolic blood pressure
(SBP, DBP), body mass index (BMI), total cholesterol, serum
creatinine, consultations (face-to-face or telephone), smoking
status (‘Ever smoker’, and ‘Never smoker’), alcohol consump-
tion (‘Non-drinker’, ‘Moderate drinker’, and ‘Heavy drinker’),
and family history of cardiovascular disease (CVD). Risk
assessments included ten-year CVD risk and the NHS health
check. The CVD risk score, was categorized into ‘‘ 10% risk
of developing CVD in the next ten years” and ‘‘>10% risk of
developing CVD in the next ten years”.
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Pre-diabetic states included coded pre-diabetes, family
history of diabetes, and gestational diabetes (for women
only). Co-morbidities were considered present at baseline if
recorded at any time prior to diagnosis. Macrovascular co-
morbidities included hypertension, coronary heart disease
(CHD, including myocardial infarction and angina), stroke,
and heart failure. Microvascular co-morbidities included
chronic kidney disease (CKD), retinopathy, and neuropathy.
To examine diabetes management following initial diag-
nosis, the date of the first antidiabetic medication prescrip-
tion (including oral antidiabetic agents and insulin),
consultation, risk factor measurement, diabetes review (in-
cluding retinopathy screening, foot examination, and offer
of dietary advice), offer of structured diabetes education,
and risk assessment following diagnosis was extracted.
2.3. Statistical analysis
As individuals attending the same general practice may have
similar levels of care provision and clinical coding, multilevel
modelling was used to account for the clustering of people
within practices. Ethnic differences in clinical characteristics
at diagnosis were derived frommultilevel multivariable linear
regression, (for age at diagnosis, HbA1c, FBG, SBP, DBP, BMI,
total cholesterol, serum creatinine, and eGFR) and multilevel
multivariable logistic regression (for deprivation quintile,
presence of pre-diabetes, family history of diabetes, gesta-
tional diabetes, family history of cardiovascular disease, any
macrovascular disease, any microvascular disease, smoking
status, alcohol consumption, CVD risk, and use of antihyper-
tensive or lipid lowering drugs) and adjusted for age at diag-
nosis, sex, and deprivation. Multilevel multivariable logistic
regression adjusted for age at diagnosis, sex, and deprivation
was used to determine ethnic differences in the odds of hav-
ing each risk factor recorded in the 12 months prior to diagno-
sis. Multivariable Cox-proportional hazards regression
adjusting for age at diagnosis, sex, deprivation, raised HbA1c
at baseline (>7.5%/53 mmol/L), and clustering by practice was
used to compare time to initiation of therapeutic and non-
therapeutic diabetes management between ethnic groups.
Follow-up time began at the date of type 2 diabetes onset
and ended at the earliest of: first antidiabetic prescription or
care process, leaving the CPRD, last data collection, or death.
2.4. Sensitivity analysis
We conducted a sensitivity analysis comparing outcomes for
those of unknown ethnicity to those of any known ethnicity.
As the recording of ethnicity was financially incentivised
under the Quality and Outcomes Framework from 2006 to
2011, and forms a core component of the annual NHS Health
Check [19] and the NHS diabetes management guidelines [20],
the recording of ethnicity can be considered a marker of
engagement with primary care. We hypothesized that indi-
viduals with missing ethnicity would have poorer risk factor
control at diagnosis, lower consultation rates, worse capture
of risk factors prior to diagnosis and slower initiation of ther-
apeutic and non-therapeutic management relative to those
with ethnicity recorded.
3. Results
From 241,891 individuals diagnosed with type 2 diabetes
between April 1st, 2004 and December 31st, 2016 in the CPRD,
179,886 adults aged 18 or over, with at least 6 months registra-
tion prior to initial diagnosis, were included in the study
(Fig. 1). Within this population, 5% (n = 8871) had been pre-
scribed an antidiabetic medication in the year prior to diagno-
sis and had their diagnosis date moved backwards. Ethnicity
was recorded for 70% of the cohort (n = 126,331), of whom
90.2% were white (n = 113,988), 5.5% were south Asian
(n = 6970), 2.3% were black African/Caribbean (n = 2944),
and 1.9% were of other ethnicities, including mixed
(n = 2409). Comparisons between the white, south Asian
and black ethnic groups are reported below.
3.1. Clinical characteristics at initial diagnosis
Crude ethnic differences in clinical characteristics at initial
diagnosis are described in Table 1 and adjusted differences
are illustrated in Fig. 2. After adjustment for sex, deprivation,
calendar year and clustering by practice, age at diagnosis was
estimated to be 9.8 years earlier in south Asian groups than
white groups (95%CI 10.14, 9.45) and 7 years earlier in black
groups (95%CI 7.46, 6.44) relative to white and 7 years ear-
lier in black groups (data) relative to white groups. Black
groups were overrepresented in the least affluent deprivation
quintile compared to white groups (OR 1.34, 95%CI 1.20–1.51),
while no differences in deprivation between white and south
Asian groups were evident.
After additionally accounting for age at diagnosis, mean
HbA1c was lower in south Asian groups
(b = 1.53, 95%CI 2.29, 0.77) and higher in black groups
relative to white groups, (b = 1.88 95%CI 0.76–3.00). BMI, total
cholesterol, and eGFR were more favourable in non-white
groups compared to white groups at diagnosis (p < 0.001),
while fasting blood glucose, blood pressure and creatinine
levels were better for south Asian groups only (p < 0.034).
The odds of having co-morbid macrovascular disease at diag-
nosis were reduced in south Asian groups and halved in black
groups relative to white (South Asian OR 0.88, 95%CI 0.80–0.96,
Black OR 0.50, 9%CI 0.43–0.58); no ethnic differences in the
odds of having diagnosedmicrovascular diseasewere evident.
Furthermore, non-white groups had markedly fewer prescrip-
tions of antihypertensive and lipid lowering drugs in the
12 months preceding diagnosis, and reduced odds of having
a CVD risk score over 10% relative to white groups
(p < 0.007) (Fig. 2).
3.2. Clinical management prior to diagnosis
In the 12 months prior to diagnosis, consultation frequency
was higher for white groups (median 10, IQR 6–17) than for
south Asian (median 9, IQR 5–15) and black groups (median
8, IQR 5–14). After adjustment for age at diagnosis, sex, depri-
vation, and clustering by practice, the consultation rate was
significantly lower for black groups relative to white (b = 0.
60, 95%CI 1.05, 0.21). Risk factor recording for south Asian
groups was better than or equivalent to non-white groups for
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9/10 risk factors of interest, and for black groups, risk factor
recording was better or equivalent for 8/10 risk factors
(Table 2).
3.3. Initiation of therapeutic and non-therapeutic
management following diagnosis
After adjustment for age, sex, deprivation, baseline HbA1c,
and clustering by practice, time to initiation of antidiabetic
therapy was faster south Asian groups (HR 1.10, 95%CI 1.07–
1.14) and black groups relative to white (HR 1.18, 95%CI
1.12–1.23). Time to first NHS health check (South Asian HR
1.30, 95%CI 1.10–1.54, Black HR 1.33, 95%CI 1.6–1.68) and offer
of structured diabetes education (South Asian HR 1.17, 95%CI
1.10–1.24, Black HR 1.44, 95%CI 1.31–1.56) was also faster in
south Asian and black groups relative to white. In contrast,
time to first consultation, risk factor measurement and dia-
betes review was longer or equivalent for both non-white
groups relative to white (Table 3).
3.4. Sensitivity analysis
Compared to those of known ethnicity (n = 126,331), individ-
uals of unknown ethnicity (n = 53,575) were younger at diag-
nosis (b = -1.13, 95%CI 1.32, 0.94), had reduced odds of risk
factors recording in the 12 months prior to diagnosis for 9/10
measures, and slower initiation of therapeutic and non-
therapeutic management post diagnosis compared to those
of known ethnicity (p < 0.001). While individuals of unknown
ethnicity had poorer control of HbA1c, FBG, and blood pres-
sure, they had more favourable cholesterol, BMI and serum
creatinine levels (p < 0.009). Contrary to expectations, individ-
uals of unknown ethnicity had greater odds of being in the
most affluent quintile of deprivation relative to those of
known ethnicity (OR 1.14, 95%CI 1.07, 1.21), and a lower preva-
lence of gestational diabetes, vascular disease, and medica-
tion use (p < 0.001, appendix figures S2 S3, appendix tables
S1,S2).
4. Discussion
We report the findings of a large population-based cohort
study examining ethnic differences in both the clinical
characteristics and clinical management of type two dia-
betes at time of diagnosis. The results show that, despite
a lower consultation rate and higher burden of pre-
diabetic states, south Asian and black groups had better
capture of risk factors, a lower age at diagnosis, and better
or equivalent cardio-metabolic profile at diagnosis. Initia-
tion of antidiabetic treatment was faster for black and
south Asian individuals, as was time to first NHS health
check and time to offer of structured education. However,
time to first consultation and measurement of risk factors
was largely slower for non-white groups.
Overall, our findings suggest that downstream inequalities
in diabetes outcomes do not appear to stem wholly from
inequalities around the time of initial diagnosis, and in fact,
highlight several positive aspects of primary care-based dia-
betes management. Firstly, the similarity of microvascular
disease between ethnic groups at time of diagnosis suggests
that non-white groups are not being diagnosed at a more sev-
ere stage of diabetes progression, and that the latency
between true onset of diabetes and clinical diagnosis does
not disadvantage ethnic minority groups. Combined with
the findings of pro-active treatment initiation and timely risk
assessments, our findings suggest that the elevated burden of
cardio-metabolic risk in non-white groups is being appropri-
ately recognized by health care professionals. Delays in risk
Fig. 1 – Study population flowchart.
4 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 0 ( 2 0 2 0 ) 1 0 8 0 0 6
Table 1 – Ethnic differences in clinical characteristics at time of initial Type 2 diabetes diagnosis.
% complete White South Asian Black Other Mixed Unknown
N 113,988 6970 2944 1854 555 53,575
Demographic characteristics Age at diagnosis (mean, SD) 100.0 63.2 (13.4) 52.6 (13.1) 55.1 (13.1) 56.3 (13.2) 54.6 (13.6) 62 (13.4)
Male, % 100.0 62,810 (55.1) 3767 (54) 1498 (50.9) 1022 (55.1) 304 (54.8) 30,643 (57.2)
Social Deprivation, % 100.0
Quintile 1 (Least deprived) 20,889 (18.3) 880 (12.6) 169 (5.7) 302 (16.3) 86 (15.5) 11,443 (21.4)
Quintile 2 22,486 (19.7) 1081 (15.5) 264 (9) 262 (14.1) 87 (15.7) 8335 (15.6)
Quintile 3 25,343 (22.2) 1456 (20.9) 611 (20.8) 368 (19.8) 120 (21.6) 9973 (18.6)
Quintile 4 22,278 (19.5) 1605 (23) 820 (27.9) 477 (25.7) 117 (21.1) 13,255 (24.7)
Quintile 5 (Most deprived) 22,992 (20.2) 1948 (27.9) 1080 (36.7) 445 (24) 145 (26.1) 10,569 (19.7)
Health behaviours Smoking status, % 72.1
Non-Smokers 32,098 (38.3) 3106 (70.6) 1227 (65.2) 683 (54.6) 189 (49.6) 16,406 (43.2)
Current Smokers 18,479 (22) 701 (15.9) 288 (15.3) 258 (20.6) 100 (26.2) 8037 (21.2)
Ex-Smokers 33,282 (39.7) 593 (13.5) 367 (19.5) 311 (24.8) 92 (24.1) 13,536 (35.6)
Risk factor level (mean, SD) HbA1c, mmol/L 52.9 63.2 (22.9) 63.9 (22.7) 66.3 (25) 65 (23.5) 66.6 (24.3) 65.2 (23)
HbA1c, % 52.9 7.9 (2.1) 8 (2.1) 8.2 (2.3) 8.1 (2.2) 8.2 (2.2) 8.1 (2.1)
Fasting blood glucose 66.4 10.5 (5) 10.1 (4.7) 10.7 (5.6) 9.9 (4.5) 10.6 (5.3) 10.7 (5.1)
SBP, mmHg 88.1 142.9 (19.7) 135.5 (18.7) 140.3 (19.5) 138.2 (19.6) 139.2 (20.5) 143.4 (20.2)
DBP, mmHg 88.1 82.3 (11.6) 82.3 (11.3) 83.8 (11.4) 82.5 (11) 84 (11.7) 82.9 (11.8)
BMI, Kg/m2 63.6 32.3 (6.1) 29.7 (5.3) 31.8 (5.9) 30.1 (5.9) 31.3 (6.4) 32.3 (6.1)
Total cholesterol, mmol/L 78.2 5.2 (1.2) 5.3 (1.2) 5.3 (1.1) 5.3 (1.2) 5.4 (1.2) 5.3 (1.2)
Serum creatinine, mmol/L 87.0 86.7 (28.6) 78.6 (27.7) 88.5 (42.3) 79.2 (27) 82.4 (25.4) 85.1 (25.9)
ACR, mg/mmol 2.5 19.6 (46.7) 20.5 (44.3) 15.7 (25.3) 38.1 (70.7) 12.9 (10.8) 20.2 (51.7)
CVD risk score (%) >10% risk in 10 years 17.6 79.1 58.4 50.8 64 53.6 78.3
Pre-diabetic indicators+ Pre-diabetes 19,007 (16.7) 1310 (18.8) 496 (16.8) 319 (17.2) 96 (17.3) 8693 (16.2)
Family history of diabetes 14,471 (12.7) 1916 (27.5) 659 (22.4) 350 (18.9) 127 (22.9) 5941 (11.1)
Gestational diabetes* 784 (1.5) 237 (7.4) 72 (5) 41 (4.9) 15 (6) 293 (1.3)
Family history of CVD 50,813 (44.6) 2874 (41.2) 858 (29.1) 660 (35.6) 212 (38.2) 23,305 (43.5)
Diagnosed co-morbidities (%)+ Any macrovascular disease 22,122 (19.4) 720 (10.3) 211 (7.2) 184 (9.9) 49 (8.8) 8975 (16.8)
Any microvascular disease 4781 (4.2) 217 (3.1) 101 (3.4) 49 (2.6) 14 (2.5) 1994 (3.7)
Hypertension 57,625 (50.6) 2320 (33.3) 1375 (46.7) 748 (40.3) 222 (40) 26,000 (48.5)
CHD 19,260 (16.9) 649 (9.3) 138 (4.7) 162 (8.7) 44 (7.9) 7746 (14.5)
Stroke 507 (0.4) 12 (0.2) 8 (0.3) 9 (0.5) 0.0 204 (0.4)
Heart failure 5117 (4.5) 133 (1.9) 90 (3.1) 33 (1.8) 8 (1.4) 2253 (4.2)
CKD 708 (0.6) 24 (0.3) 16 (0.5) 6 (0.3) 3 (0.5) 267 (0.5)
Retinopathy 2111 (1.9) 106 (1.5) 56 (1.9) 26 (1.4) 9 (1.6) 979 (1.8)
Neuropathy 2215 (1.9) 101 (1.4) 38 (1.3) 20 (1.1) 2 (0.4) 845 (1.6)
Medications prescribed (%)+ Antihypertensives 69,988 (61.4) 2796 (40.1) 1441 (48.9) 838 (45.2) 258 (46.5) 31,095 (58)
Lipid lowering 52,721 (46.3) 2566 (36.8) 926 (31.5) 729 (39.3) 190 (34.2) 22,834 (42.6)
* Baseline covariate data taken at the date closest to Type 2 diabetes diagnosis in the 12 months preceding diagnosis, (gestational diabetes among women only).
+ Pre-diabetic indicators, Diagnosed co-morbidities and medications assumed to be present if recorded and absent if not recorded.
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factor measurement and diabetes review may reflect lower
burden of cardio-metabolic risk at time of diagnosis or may
be indicative of growing ethnic disparities with respect to
longer-term diabetes management.
4.1. Comparisons with existing literature
To date, only two other UK based studies have reported ethnic
differences in clinical severity at initial diagnosis of type 2
Table 2 – Risk factor recording and consultations in the 12 months prior to type 2 diabetes diagnosis.
% with risk factor recorded Adjusted difference
White South Asian Black South Asian vs. White Black vs. White
N 113,988 6970 2944
Risk Factors % % % OR 95%CI p.val OR 95%CI p.val
HbA1c 51.8 62.3 60.9 1.37 (1.30, 1.45) <0.001 1.17 (1.08, 1.27) <0.001
Glucose 66.2 60.8 59.4 1.02 (0.97, 1.08) 0.455 0.88 (0.81, 0.95) 0.002
Blood Pressure 88.9 85.0 87.0 0.99 (0.92, 1.06) 0.700 1.08 (0.97, 1.19) 0.162
BMI 64.1 64.6 64.6 0.98 (0.93, 1.03) 0.345 1.00 (0.92, 1.08) 0.950
Total Cholesterol 78.9 80.8 78.6 1.12 (1.06, 1.19) <0.001 1.01 (0.92, 1.09) 0.892
Creatinine 87.7 85.3 84.9 1.14 (1.07, 1.21) <0.001 1.07 (0.97, 1.17) 0.163
Urine ACR 2.4 1.9 2.1 1.18 (0.96, 1.44) 0.117 1.18 (0.89, 1.57) 0.242
Smoking Status 73.6 63.1 63.9 0.72 (0.69, 0.76) <0.001 0.75 (0.70, 0.81) <0.001
Risk assessments
NHS Health Check 4.1 8.4 10.2 1.55 (1.40, 1.73) <0.001 1.49 (1.29, 1.72) <0.001
CVD risk score 18.7 22.3 24.9 1.05 (0.98, 1.12) 0.159 1.22 (1.11, 1.35) <0.001
Consultations Median (IQR) b CI95% p. val b CI95% p. val
Number of consultations 10 (6–17) 9 (5–15) 8 (5–14) 0.10 (0.40, 0.18) 0.452 0.60 (1.05, 0.21) 0.003
*Logistic and linear regression models adjusted for age at baseline, sex, deprivation, and clustering by practice.
Fig. 2 – Ethnic differences in clinical severity at type 2 diabetes diagnosis. *All models adjust for age at diagnosis, sex,
deprivation, and clustering by practice.
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Table 3 – Time to therapeutic and non-therapeutic clinical management following type 2 diabetes diagnosis.
% receiving clinical management Median time to first clinical event (months) Adjusted HR
White South Asian Black White South Asian Black SA vs. White Black vs. White
N 113,988 6970 2944 HR CI95% p.val HR CI95% p.val
First post-diagnosis consultation 99.9 99.7 99.8 0.1 0.1 0.1 0.84 (0.81,0.86) <0.001 0.92 (0.89,0.96) <0.001
Initiation of antidiabetic therapy 73.2 80.9 78 3.6 2.2 1.8 1.10 (1.07,1.14) <0.001 1.18 (1.12,1.23) <0.001
Risk factor measurement
HbA1c 94.8 92.4 89.7 2.7 3.2 3.2 0.93 (0.91,0.96) <0.001 0.88 (0.84,0.91) <0.001
Blood Glucose 61.7 58.1 56.2 10.5 10.3 9.2 0.94 (0.91,0.98) 0.001 0.96 (0.91,1.01) 0.125
Urine ACR 59 53.4 56.4 11.4 12.2 10.6 1.01 (0.98,1.05) 0.504 1.05 (1.00,1.11) 0.055
BMI 92.7 91.2 88.6 1.7 2.1 2.4 0.96 (0.94,0.99) 0.010 0.97 (0.93,1.01) 0.115
Blood Pressure 96.3 94.2 93.5 1.4 1.6 1.4 0.91 (0.88,0.93) <0.001 1.00 (0.96,1.04) 0.872
Total Cholesterol 92.5 90.2 87.6 3.7 4.3 4.1 0.99 (0.97,1.02) 0.667 0.97 (0.93,1.02) 0.220
Smoking Status 93.2 90.4 86.6 3.0 3.4 3.6 0.90 (0.87,0.92) <0.001 0.87 (0.83,0.91) <0.001
Serum Creatinine 94.3 90.7 88.3 3.2 4.0 3.8 0.94 (0.92,0.97) <0.001 0.93 (0.89,0.97) <0.001
Diabetes review
Diabetes Review 82.4 81.1 75.9 6.0 6.7 6.8 1.03 (1.00,1.06) 0.076 1.03 (0.98,1.08) 0.194
Retinopathy Screen 41.1 37.9 41.8 22.8 22.1 19.2 0.98 (0.94,1.02) 0.305 0.93 (0.87,0.98) 0.014
Foot Examination 40 26.9 25.7 26.5 29.8 25.8 0.86 (0.81,0.90) <0.001 0.92 (0.85,0.99) 0.027
Offer of dietary advice 6.3 3.3 1.5 47.6 43.2 38.2 0.81 (0.71,0.94) 0.005 0.64 (0.48,0.87) 0.004
Structured diabetes education offered 17.2 22.5 25 48.3 40.2 31.0 1.17 (1.10,1.24) <0.001 1.44 (1.32,1.56) <0.001
Risk assessment
CVD risk score 15.4 20.6 18.6 43.4 34.2 30.8 1.02 (0.96,1.09) 0.463 1.06 (0.96,1.16) 0.249
NHS Health Check 1.7 2.8 3.1 52.1 44.9 38.1 1.30 (1.10,1.54) 0.002 1.32 (1.05,1.67) 0.019
*All models adjust for age at baseline, sex, deprivation, raised HbA1c at baseline, and clustering by practice. Time to initiation of antidiabetic therapy restricted to those free from antidiabetic
medication in 12 months prior to diagnosis date.
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diabetes [21,22]. The first, a London based study of 1506 indi-
viduals, found that diagnosis was ten years earlier for both
black and south Asian populations, and that both non-white
groups had lower levels of glycaemia and vascular complica-
tions [21]. The second was a 2003 survey of 1899 individuals
with type 2 diabetes which reported equivalent access to dia-
betes care between black and white individuals- providing
further support to our findings of equity between ethnic
groups with respect to clinical care before and after diagnosis
[22].
Improvements in both quality of diabetes care and risk
factor profiles of people with type 2 diabetes in the UK may
be related to several overlapping causes. Firstly, the introduc-
tion of the Quality and Outcomes Framework (QOF), which
incentivises achievement of quality targets for the care of
individuals with chronic conditions, has both improved over-
all standards of diabetes care and reduced variations in dia-
betes care provision [23–25]. However, one study found that,
though QOF incentivisation had accelerated short-term
improvements in blood pressure and cholesterol, ethnic dis-
parities in HbA1c remained – a finding echoed in our own
study which showed that black people had significantly
higher HbA1c at diagnosis, despite equivalence of other risk
factors [26].
Secondly, awareness amongst health care practitioners
about ethnic differences in cardio-metabolic risk has
increased steadily and may be responsible for the pro-active
management of diabetes in non-white groups. Ethnicity has
now been incorporated into clinical guidance documents for
hypertension, obesity, type 2 diabetes, and smoking cessation
[27–29]. Specifically, guidelines for the prevention of type 2
diabetes in people at high risk, specify that individuals from
ethnic minority populations should be encouraged to undergo
a risk assessment for type 2 diabetes [20]. In May 2018, a new
guideline for promoting health amongst ethnic minority
groups, was published – indicating that further reductions
in ethnic disparities may become apparent over time [30].
Thirdly, improvements in risk factor profiles at diagnosis
may be part of a larger trend of decreasing vascular disease
across the developedworld [31]. A 2017 study of trends in type
2 diabetes incidence, prevalence and mortality in the UK
found a 32% decrease in all-cause mortality between 2004
and 2014, and a 2% increase in prevalence, thought to be dri-
ven by better survival rather than increasing incidence [32].
The findings of our study reflect these emerging trends, with
reductions in ethnic inequalities likely driven by temporal
improvements in population levels of risk factors, quality of
clinical care, awareness of established ethnic differences in
outcomes, and increased effectiveness of novel pharmacolog-
ical therapies.
4.2. Strengths
The strengths and limitations of routine electronic health
records (EHRs) for diabetes research have been comprehen-
sively outlined in a recent review [33]. In this study, the sam-
ple size was large and drawn from a representative
denominator population, allowing sufficient power to detect
differences between the main ethnic groups in the UK. The
cohort was identified using a validated algorithm, designed
to minimize misclassification of diabetes type [34]. In order
to account for the step change in diabetes management fol-
lowing the introduction of QOF, entry into the study cohort
was restricted to individuals diagnosed with type 2 diabetes
from 2004 onwards. Recent improvements in the complete-
ness of ethnicity recording in the CPRD as part of QOF have
facilitated a more robust examination of ethnic differences
in conditions managed largely in primary care [17]. Linkage
to deprivation data enabled us to separate the influences of
ethnicity and deprivation, which are often conflated when
examining health disparities. Restricting the study sample
to people with at least 6 months of continuous registration
prior to their initial diagnosis of type 2 diabetes ensured that
diagnoses were truly incident and that all outcomes of inter-
est were measured as close to initiation of diabetes manage-
ment as possible. General practice characteristics such as
size, and participation in local enhanced service schemes
have been found to play a large role in observed variations
in quality of diabetes care [35]. By accounting for the cluster-
ing of people within practices, we were able to appropriately
account for the influence of practice level factors on ethnic
disparities.
4.3. Limitations
As EHRs are primarily used for patient care rather than
research, data quality and completeness can vary signifi-
cantly depending on the time-period, disease area, and
indicator of interest. Though financial incentivisation has
standardized many aspects of diabetes care, shared decision
is now the preferred model for management of many long-
term conditions. As such, observed differences in diabetes
indicators may be due to active choices by the individual
and provider to deviate from standard management plans
in order to manage competing priorities. Ethnicity data
was not available for 30% of the study cohort, which may
have introduced bias. Since ethnicity data are unlikely to
be missing at random, it would have been inappropriate
to impute these data. Sensitivity analyses showed that indi-
viduals with unknown ethnicity were younger at diagnosis
and, surprisingly, less deprived than those of known ethnic-
ity. Coupled with the findings of heterogeneity in clinical
profile at diagnosis (poorer risk factor levels but fewer co-
morbidities), it is likely that this is a mixed group encom-
passing younger, healthier, and more affluent individuals
who may not need to access healthcare, and individuals
who are less healthy, or less able to access care. Deprivation
scores derived from the postcode of the general practice
were used for 40% of participants without permissions for
linkage to individual level data. The relationship between
practice level and individual level deprivation will vary
greatly between individuals, potentially underestimating
the true confounding effect of deprivation on the associa-
tion between ethnicity and diabetes when using practice
level as a proxy.
The dataset did not include information on genetic risk
factors, early life exposures, migration history, diet and exer-
cise, or any measures of health seeking behaviour or differ-
ences in attitudes towards medications and thus
unmeasured confounding may have influenced the results.
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Future studies combining routine EHRs with cohort studies
such as the UK Biobank will be valuable in obtaining a com-
plete picture of an individual’s health across the life course.
4.4. Conclusions
Overall, we find limited evidence of systematic ethnic
inequalities in identification of type 2 diabetes and manage-
ment of cardio-metabolic risk around the time of initial
diagnosis. Findings from this study may be illustrative of
a wider trend of shrinking inequalities in diabetes care.
Additional investigations into the origin and implications
of missingness of ethnicity data are warranted. Future work
examining the extent to which ethnic differences are
explained by genetic factors and whether ethnic disparities
manifest later in the care pathway, for example, in relation
to long-term risk factor control as suggested here, will be
necessary to understand how patterns of ethnic disparities
in risk factor control and long-term outcomes are evolving
in the UK.
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